Loading stock data…
Liquidia Corporation (LQDA)
$75.12-3.05 (-3.90%)
After Hours$75.12+0.00 (+0.00%)· Last close Jun 29
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Liquidia Corporation in the Healthcare sector is trading at $75.12 with a market capitalization of $6.2B. Wall Street consensus targets $74.25 (8 analysts), implying a -1.2% move over the next 12 months. The stock is currently near its 52-week high of $79.41, remaining 96.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $132.87M↑ | $92.02M↑ | $54.34M↑ | $8.84M↑ | $3.12M |
| Gross Profit | $121.01M↑ | $84.97M↑ | $51.17M↑ | $7.34M↑ | $1.60M |
| Operating Income | $61.50M↑ | $19.79M↑ | $1.77M↑ | -$37.51M↓ | -$35.42M |
| Net Income | $52.86M↑ | $14.55M↑ | -$3.53M↑ | -$41.58M↓ | -$38.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.54%
Volume
Today's trading volume
2.55M
Recent News
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
Investing.com -- Bank of America downgraded four U.S. biopharmaceutical companies, lowering ratings on Alkermes, Amphastar Pharmaceuticals and Biohaven to Underperform, while cutting Liquidia to Neutral, citing a combination of stretched valuations, uncertain near-term catalysts and a rebalancing of its ratings across the sector.
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Liquidia (LQDA) Stock Fair Value Rises After Analysts Rework Legal Risk And Earnings
Analysts covering Liquidia have been revisiting their models, with revised price targets on the stock that range from US$75 to US$109 and an updated fair value estimate of US$72.38 per share. These shifts are being linked to fresh Street commentary that balances optimism around potential earnings power and legal interpretations with ongoing uncertainty around the '327 patent bench trial decision. As you read on, you will see how to follow this evolving narrative and what to watch as new...
Why Liquidia (LQDA) Is Up 10.0% After YUTREPIA Drives Its Shift To Commercial Stage
In recent months, Liquidia Corporation has moved from a development-stage biotech to a commercial-stage company, with its PRINT-enabled inhaled treprostinil therapy YUTREPIA now driving its early commercial performance and attracting increased analyst attention. This shift has coincided with a marked improvement in earnings and sales estimates and a top Zacks Rank, signaling that YUTREPIA’s market traction is reshaping how investors view Liquidia’s business profile and risk-reward...
Liquidia (LQDA) Reaches Commercial Stage As YUTREPIA Draws Institutional Interest
Liquidia (NasdaqCM:LQDA) has moved from a development-stage to a commercial-stage company, driven by the launch of YUTREPIA. The transition is accompanied by a more positive company outlook and rising attention from institutional investors. This shift centers on YUTREPIA as a commercial product, rather than solely on clinical data or trial milestones. For investors tracking specialty pharma, Liquidia now sits in a different bucket, with YUTREPIA pushing the company into commercial-stage...